Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Djibouti
ACTRN12624000909527Phase 4Completed
- Sponsor
- Ministry of Health of Djibouti
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether + lumefantrine in malaria and Falciparum malaria (PF), sponsored by Ministry of Health of Djibouti. Primary endpoint: Proportion of treatment failures. Started Feb 2024; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12624000909527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000909527.